LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) secured patent protection in Europe and Australia through March 2041 for the liquid formulation of its investigational lung-disease therapy MOLBREEVI, expanding the intellectual-property barriers around a drug the company is developing for autoimmune pulmonary alveolar proteinosis.
The European Patent Office granted European patent No. 4121000 covering the formulation, while the Australian Patent Office granted corresponding protection through the same expiration date.
The patents add to protection Savara and PARI secured in Europe in December 2025 for the MOLBREEVI drug-device combination using PARI’s proprietary eFlow Nebulizer System. That jointly held European patent runs through March 2043.
Savara is pursuing equivalent patent applications in the U.S., including protection for the drug-device combination, according to the company.
“These patents further strengthen the company’s intellectual property portfolio for MOLBREEVI, providing an additional layer of defense in markets with no approved alternatives,” Chief Legal Officer Kate McCabe said.
MOLBREEVI is an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF, administered through the eFlow nebulizer. The therapy remains investigational and has not been approved for commercial use.
The U.S. Food and Drug Administration has granted MOLBREEVI Fast Track, Breakthrough Therapy and Orphan Drug designations for autoimmune pulmonary alveolar proteinosis. The European Medicines Agency has also granted Orphan Drug designation, while U.K. regulators have awarded Innovation Passport and Promising Innovative Medicine designations.
Autoimmune pulmonary alveolar proteinosis, or autoimmune PAP, is a rare lung disease in which antibodies neutralize GM-CSF, impairing immune cells responsible for clearing excess surfactant from the lungs.
The resulting accumulation of surfactant in the alveoli can interfere with gas exchange and cause shortness of breath, coughing and fatigue. The disease can lead to complications including lung fibrosis and, in severe cases, the need for a lung transplant.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.